Baidu
map

Lancet Infect Dis:耐药性肺结核的流行趋势

2017-05-10 zhangfan MedSci原创

印度、菲律宾、俄罗斯和南非4个国家的多药耐药以及扩大耐药型肺结核比例将达到较高水平,加强药物抵抗预防将有助于减缓耐药性肺结核在全球的流行趋势

多药耐药(MDR)和广泛耐药(XDR)肺结核在全球范围约90个国家和地区均有发现。近日,研究人员调查了印度、菲律宾、俄罗斯和南非4个国家的MDR以及XDR结核发病趋势。

研究人员预测估计了MDR和XDR结核事件发病率以及由于MDR和XDR导致的耐药事件发生情况,并预计了药物耐药对上述国家医疗卫生负担的影响。

研究发现,模型预测到2040年,MDR肺结核将占据较高的肺结核的比例,印度12.4%、菲律宾8.9%、俄罗斯32.5%、南非5.7%,XDR肺结核也将占据较高的肺结核的比例,印度8.9%、菲律宾9.0%、俄罗斯9.0%、南非8.5%。2000至2040年间,药物抵抗将导致30%左右的多药耐药肺结核;2000年药物抵抗导致的扩大耐药肺结核的比例为80%,在2040年预计为50%。

预测研究表明,印度、菲律宾、俄罗斯和南非4个国家的多药耐药以及扩大耐药型肺结核比例将达到较高水平,加强药物抵抗预防将有助于减缓耐药性肺结核在全球的流行趋势。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012246, encodeId=a0f32012246c0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 21 04:46:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992810, encodeId=81c019928106e, content=<a href='/topic/show?id=da78803890e' target=_blank style='color:#2F92EE;'>#耐药性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80389, encryptionId=da78803890e, topicName=耐药性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Mon Dec 11 18:46:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828935, encodeId=95641828935fd, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu May 25 06:46:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254061, encodeId=d084125406169, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 12 00:46:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196249, encodeId=e72319624914, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Wed May 10 15:09:14 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196197, encodeId=35d019619e84, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Wed May 10 12:11:04 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012246, encodeId=a0f32012246c0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 21 04:46:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992810, encodeId=81c019928106e, content=<a href='/topic/show?id=da78803890e' target=_blank style='color:#2F92EE;'>#耐药性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80389, encryptionId=da78803890e, topicName=耐药性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Mon Dec 11 18:46:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828935, encodeId=95641828935fd, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu May 25 06:46:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254061, encodeId=d084125406169, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 12 00:46:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196249, encodeId=e72319624914, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Wed May 10 15:09:14 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196197, encodeId=35d019619e84, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Wed May 10 12:11:04 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012246, encodeId=a0f32012246c0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 21 04:46:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992810, encodeId=81c019928106e, content=<a href='/topic/show?id=da78803890e' target=_blank style='color:#2F92EE;'>#耐药性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80389, encryptionId=da78803890e, topicName=耐药性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Mon Dec 11 18:46:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828935, encodeId=95641828935fd, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu May 25 06:46:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254061, encodeId=d084125406169, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 12 00:46:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196249, encodeId=e72319624914, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Wed May 10 15:09:14 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196197, encodeId=35d019619e84, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Wed May 10 12:11:04 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-05-25 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=2012246, encodeId=a0f32012246c0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 21 04:46:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992810, encodeId=81c019928106e, content=<a href='/topic/show?id=da78803890e' target=_blank style='color:#2F92EE;'>#耐药性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80389, encryptionId=da78803890e, topicName=耐药性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Mon Dec 11 18:46:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828935, encodeId=95641828935fd, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu May 25 06:46:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254061, encodeId=d084125406169, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 12 00:46:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196249, encodeId=e72319624914, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Wed May 10 15:09:14 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196197, encodeId=35d019619e84, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Wed May 10 12:11:04 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2012246, encodeId=a0f32012246c0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 21 04:46:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992810, encodeId=81c019928106e, content=<a href='/topic/show?id=da78803890e' target=_blank style='color:#2F92EE;'>#耐药性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80389, encryptionId=da78803890e, topicName=耐药性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Mon Dec 11 18:46:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828935, encodeId=95641828935fd, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu May 25 06:46:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254061, encodeId=d084125406169, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 12 00:46:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196249, encodeId=e72319624914, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Wed May 10 15:09:14 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196197, encodeId=35d019619e84, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Wed May 10 12:11:04 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-05-10 绛珠草小姐

    学习了,谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2012246, encodeId=a0f32012246c0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 21 04:46:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992810, encodeId=81c019928106e, content=<a href='/topic/show?id=da78803890e' target=_blank style='color:#2F92EE;'>#耐药性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80389, encryptionId=da78803890e, topicName=耐药性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Mon Dec 11 18:46:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828935, encodeId=95641828935fd, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu May 25 06:46:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254061, encodeId=d084125406169, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 12 00:46:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196249, encodeId=e72319624914, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Wed May 10 15:09:14 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196197, encodeId=35d019619e84, content=签到学习了很多。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Wed May 10 12:11:04 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-05-10 Chongyang Zhang

    签到学习了很多。

    0

相关资讯

肺结核是一种自身免疫性疾病?

近期,《TrendsinImmunology》期刊发表一篇文章揭示,肺结核致病细菌会“欺骗”免疫系统,使得免疫系统自主攻击健康肺组织,并促成感染菌进入肺部,造成损伤。这一最新发现有望为疫苗、治疗药物的研发提供新线索。肺结核是全球死亡人数最多的传染病。2015年,全球约有1040万人患结核病,180万人死于结核病,且95%病例发生在中低下收入水平国家。而我国是全球22个结核病流行最严重的国家之一。防

NEJM:偶然发现的油胸 -案例报道

考虑到该患者的肺结核治疗史,最可能的诊断是油胸-肺结核的一种治疗方式,已经废弃了多年,涉及将油灌注进入胸膜腔使肺塌陷。通常情况下,治疗后,油被吸收的过程可以持续长达2年。然而,无症状的患者有时会失访,并且油留在原位,正如在这个病人身上发生的一样。长期并发症,包括重叠感染和气道阻塞,也有报导。这个病人没有出现并发症或油胸相关症状

Science:利用小分子SMARt-420逆转结核分枝杆菌的抗生素耐药性

在一项新的研究中,来自瑞典、法国、比利时和瑞士的一个研究团队发现一种方法逆转对一种用于治疗肺结核的抗生素药物产生的耐药性。在他们发表在2017年3月17日的Science期刊上的论文中,该团队描述了他们如何筛选激活用于活化ethionaide的不同通路的化合物。Ethionaide是一种被用来治疗肺结核的前体分子,在体内经过代谢后产生一种真正有

世界防治结核病日 盘点近年来结核病研究领域的亮点成果

今年3月24日是第22个世界防治结核病日,今年的结核病日的宣传主题是“社会共同努力,消除结核危害”。2016年,世卫组织报告全球1040万人患结核病,2015年有180万因结核病死亡,如今结核病已经成为世界上最大的传染病杀手,这种疾病深深植根于人权和尊严受限的人群中。 近些年来,科学家们在结核病研究领域取得了很多突破性的进展,本文中小编就对此进行了整理,与各位一起共同学习!

Nature子刊:科学家有望开发出治疗肺结核的靶向性药物

图片来源:www.phys.org 近日,一项刊登在国际杂志Nature Chemical Biology上的研究报告中,来自普渡大学的研究人员通过研究发现了拦截机体免疫系统对肺结核产生反应的机制,这或许就为科学家们提供了一种新型药物靶点来帮助开发治疗肺结核的新型药物。文章中研究者阐明了结核分枝杆菌如何关闭人类细胞对细菌产生的免疫反应。 肺结核是一种因感染结核分枝杆菌而引发的传染性疾病,该

Nat Commun:土壤细菌衍生的特殊化合物或有望成为抵御肺结核的新型疗法

日前,一项刊登在国际杂志Nature Communications上的研究报告中,来自英国华威大学等多个机构的研究人员通过研究利用来自土壤中细菌衍生的化合物开发出了治疗肺结核(TB)的新型疗法。 文章中,研究者发现,某种土壤细菌所产生的化合物能够有效抑制其周围的细菌生长,利用合成化学技术,研究

Baidu
map
Baidu
map
Baidu
map